Pharma Sector

Symbiotec Pharmalab IPO opened for subscription on August 24, 2026. The latest GMP stands at ₹409 against the IPO price of ₹988, indicating an estimated listing price of ₹1,397 and a potential premium of 41.40%.

The renewed US-Iran conflict and uncertainty around the Strait of Hormuz are putting oil prices and global markets under pressure. Here’s how prolonged disruption could affect crude, inflation and stock markets in India, the US and Europe.

Symbiotec Pharmalab IPO GMP rises to ₹320 on August 21, 2026. At the upper IPO price of ₹988, the GMP indicates an estimated listing price of ₹1,308, or a potential 32.39% premium. Check IPO details, financials and valuation.

Indian benchmark indices ended sharply higher on August 3, with the Sensex gaining 544 points and the Nifty closing at 24,774. Strong buying in IT stocks, easing crude oil prices, improving FII sentiment, and the rollout of the new Closing Auction Session (CAS) drove the rally, while investors remained focused on the upcoming RBI policy meeting.

Indian stock markets ended sharply higher on July 29, 2026, with the Sensex gaining 888.68 points and the Nifty closing at 24,250.20. The rally was driven by sustained buying in IT stocks, positive FII inflows, lower market volatility, and expectations of an unchanged US Federal Reserve interest rate. Infosys led the IT surge, while broad-based gains across FMCG, Metals, Pharma, and Financials boosted overall market sentiment.

Dr. Lal Path Labs shares reached a fresh 52-week high of ₹1,894.90 following strong Q1 FY27 performance, supported by robust revenue growth, higher profitability, improved operating margins, and positive management commentary. The company reported a 28% YoY rise in consolidated net profit, strong volume growth, and improved business momentum, strengthening investor confidence in its long-term growth prospects.

Indian benchmark indices staged a strong recovery on July 27, 2026, ending a five-session losing streak. The Nifty and Sensex gained nearly 1% each, supported by easing US-Iran tensions, a sharp decline in crude oil prices, improved global sentiment, and strong buying in IT, Media, Realty, and Auto stocks. Infosys led the IT rally following leadership transition news and positive brokerage sentiment.

Manipal Health Enterprises IPO will open for subscription from July 29 to July 31, 2026, with a price band of ₹560-590 per share. Here's everything investors need to know, including the latest GMP, financial performance, issue details, and investment outlook.

Sensex and Nifty extended losses for the fifth consecutive session as rising crude oil prices, US-Iran tensions, weak Wall Street cues, and higher bond yields weighed on investor sentiment. IT and Media stocks outperformed, while Auto stocks led the decline.

Dr. Reddy's Laboratories stock fell nearly 7% to a fresh 52-week low of ₹1,101 after reporting disappointing Q1 FY27 earnings. A sharp decline in profit, weaker North America sales, margin compression, Semaglutide API quality issues, and cautious analyst commentary triggered heavy selling in the pharma stock.